Skip to content
Peptide.Guide
ExperimentalCognitiveOralAs usedFDA-banned; serious cardiovascular events reportedPartial data

DMAA

1,3-Dimethylamylamine

Potent sympathomimetic stimulant once sold in pre-workout supplements; banned by the FDA in dietary supplements due to safety concerns.

Read dosing protocol

◆ Editorial note

Sympathomimetic stimulant, not a peptide. Banned by FDA in dietary supplements.

§ 01   Overview

Overview

Potent sympathomimetic stimulant once sold in pre-workout supplements; banned by the FDA in dietary supplements due to safety concerns.

Linked to serious adverse events including strokes and deaths in healthy users.

§ 02   Mechanism

Mechanism of action

DMAA is a synthetic vasoconstrictor and releaser of norepinephrine, producing stimulant, appetite-suppressing, and pressor effects.

  • 01Strong stimulant and focus effects (subjective)
  • 02Appetite suppression

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
25 – 75 mg (historic pre-workout doses)
Route
Oral
Frequency
As used

§ 04   Evidence

Evidence & research

Experimental

Linked to serious adverse events including strokes and deaths in healthy users.

FDA Status

FDA declared DMAA illegal in dietary supplements (2013).

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Severe hypertension
  • 02Strokes and deaths reported
  • 03Cardiac arrhythmias

Contraindications

  • 01Cardiovascular disease
  • 02Hypertension
  • 03Any stimulant sensitivity
◆   In this categoryMore from Cognitive
01

Semax

Synthetic ACTH(4-10) analog developed in Russia for stroke rehabilitation and cognitive enhancement.

Preclinical
02

Selank

Synthetic tuftsin analog with anxiolytic and immunomodulatory effects, developed as a non-benzodiazepine alternative.

Preclinical
03

Alpha-GPC

Choline-delivery compound that raises brain choline and acetylcholine levels, commonly used as a nootropic.

Clinical
04

Dihexa

Angiotensin IV analog with potent synaptogenic activity in preclinical models; potency much higher than BDNF in some assays.

Preclinical
05

Fladrafinil

Fluorinated analog of adrafinil/modafinil with similar wakefulness-promoting effects. Research chemical status.

Experimental

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.